SG Americas Securities LLC Purchases 8,762 Shares of TransMedics Group, Inc. $TMDX

SG Americas Securities LLC grew its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 125.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,725 shares of the company’s stock after buying an additional 8,762 shares during the quarter. SG Americas Securities LLC’s holdings in TransMedics Group were worth $1,913,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in TMDX. Royal Bank of Canada raised its holdings in shares of TransMedics Group by 47.9% in the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after acquiring an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in TransMedics Group by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after acquiring an additional 868 shares in the last quarter. Goldman Sachs Group Inc. increased its position in TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after purchasing an additional 86,721 shares during the period. Russell Investments Group Ltd. increased its position in TransMedics Group by 13.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after purchasing an additional 938 shares during the period. Finally, State Board of Administration of Florida Retirement System raised its holdings in shares of TransMedics Group by 6.4% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 8,248 shares of the company’s stock valued at $1,105,000 after purchasing an additional 495 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

TMDX has been the subject of several research reports. JPMorgan Chase & Co. upped their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Wall Street Zen downgraded shares of TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Canaccord Genuity Group upped their target price on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Stifel Nicolaus increased their target price on TransMedics Group from $115.00 to $130.00 and gave the company a “hold” rating in a research report on Monday, March 9th. Finally, Needham & Company LLC lifted their price target on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Seven investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $152.33.

Insider Buying and Selling at TransMedics Group

In other news, insider Nicholas Corcoran sold 2,966 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $412,629.92. Following the completion of the transaction, the insider owned 29,831 shares of the company’s stock, valued at $4,150,088.72. The trade was a 9.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Gerardo Hernandez sold 7,236 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $147.21, for a total value of $1,065,211.56. Following the completion of the sale, the chief financial officer owned 14,689 shares in the company, valued at $2,162,367.69. The trade was a 33.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 16,205 shares of company stock worth $2,353,002. Insiders own 7.00% of the company’s stock.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $100.69 on Monday. The business’s 50-day moving average is $126.78 and its 200 day moving average is $126.87. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 6.59. TransMedics Group, Inc. has a 1 year low of $62.23 and a 1 year high of $156.00. The firm has a market capitalization of $3.45 billion, a P/E ratio of 20.55 and a beta of 2.09.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.